Swiss-Prot entry
ID KCMB4_HUMAN STANDARD; PRT; 210 AA.
AC Q86W47; Q8IVR3; Q9NPA4; Q9P0G5;
DT 05-JUL-2004 (Rel. 44, Created)
DT 05-JUL-2004 (Rel. 44, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Calcium-activated potassium channel beta subunit 4 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 4) (Maxi K channel beta
DE subunit 4) (BK channel beta subunit 4) (Slo-beta 4) (K(VCA)beta 4)
DE (Charybdotoxin receptor beta subunit 4) (BKbeta4) (Hbeta4).
GN Name=KCNMB4;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE, FUNCTION, GLYCOSYLATION, AND VARIANT ILE-199.
RX MEDLINE=20266405; PubMed=10792058 [NCBI, ExPASy, EBI, Israel, Japan]; DOI=10.1073/pnas.100118597;
RA Meera P., Wallner M., Toro L.;
RT "A neuronal beta subunit (KCNMB4) makes the large conductance,
RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and
RT iberiotoxin.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567(2000).
RN [2]
RP NUCLEOTIDE SEQUENCE, FUNCTION, AND TISSUE SPECIFICITY.
RX PubMed=10828459 [NCBI, ExPASy, EBI, Israel, Japan]; DOI=10.1016/S0014-5793(00)01584-2;
RA Behrens R., Nolting A., Reimann F., Schwarz M., Waldschuetz R.,
RA Pongs O.;
RT "hKCNMB3 and hKCNMB4, cloning and characterization of two members of
RT the large-conductance calcium-activated potassium channel beta subunit
RT family.";
RL FEBS Lett. 474:99-106(2000).
RN [3]
RP NUCLEOTIDE SEQUENCE, FUNCTION, INTERACTION WITH KCNMA1, AND TISSUE
RP SPECIFICITY.
RX MEDLINE=20158960; PubMed=10692449 [NCBI, ExPASy, EBI, Israel, Japan]; DOI=10.1074/jbc.275.9.6453;
RA Brenner R., Jegla T.J., Wickenden A., Liu Y., Aldrich R.W.;
RT "Cloning and functional characterization of novel large conductance
RT calcium-activated potassium channel beta subunits, hKCNMB3 and
RT hKCNMB4.";
RL J. Biol. Chem. 275:6453-6461(2000).
RN [4]
RP NUCLEOTIDE SEQUENCE, AND INTERACTION WITH KCNMA1.
RC TISSUE=CNS;
RX MEDLINE=20266164; PubMed=10804197 [NCBI, ExPASy, EBI, Israel, Japan];
RA Weiger T.M., Holmqvist M.H., Levitan I.B., Clark F.T., Sprague S.,
RA Huang W.-J., Ge P., Wang C., Lawson D., Jurman M.E., Glucksmann M.A.,
RA Silos-Santiago I., DiStefano P.S., Curtis R.;
RT "A novel nervous system beta subunit that downregulates human large
RT conductance calcium-dependent potassium channels.";
RL J. Neurosci. 20:3563-3570(2000).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Eye, and Lymph;
RX MEDLINE=22388257; PubMed=12477932 [NCBI, ExPASy, EBI, Israel, Japan]; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [6]
RP PHOSPHORYLATION, AND MUTAGENESIS OF THR-11; SER-17 AND SER-210.
RX PubMed=11790768 [NCBI, ExPASy, EBI, Israel, Japan]; DOI=10.1074/jbc.M107682200;
RA Jin P., Weiger T.M., Wu Y., Levitan I.B.;
RT "Phosphorylation-dependent functional coupling of hSlo calcium-
RT dependent potassium channel and its hbeta 4 subunit.";
RL J. Biol. Chem. 277:10014-10020(2002).
RN [7]
RP GLYCOSYLATION, AND MUTAGENESIS OF ASN-53 AND ASN-90.
RX PubMed=12223479 [NCBI, ExPASy, EBI, Israel, Japan]; DOI=10.1074/jbc.M205795200;
RA Jin P., Weiger T.M., Levitan I.B.;
RT "Reciprocal modulation between the alpha and beta 4 subunits of hSlo
RT calcium-dependent potassium channels.";
RL J. Biol. Chem. 277:43724-43729(2002).
RN [8]
RP REVIEW.
RX PubMed=12136044 [NCBI, ExPASy, EBI, Israel, Japan];
RA Orio P., Rojas P., Ferreira G., Latorre R.;
RT "New disguises for an old channel: MaxiK channel beta-subunits.";
RL News Physiol. Sci. 17:156-161(2002).
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
CC KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel
CC diversity. Decreases the gating kinetics and calcium sensitivity
CC of the KCNMA1 channel, but with fast deactivation kinetics. May
CC decrease KCNMA1 channel openings at low calcium concentrations but
CC increases channel openings at high calcium concentrations. Makes
CC KCNMA1 channel resistant to 100 nM charybdotoxin (CTX) toxin
CC concentrations.
CC -!- SUBUNIT: Interacts with KCNMA1 tetramer. There are probably 4
CC molecules of KCMNB4 per KCNMA1 tetramer.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- TISSUE SPECIFICITY: Predominantly expressed in brain. In brain, it
CC is expressed in the cerebellum, cerebral cortex, medulla, spinal
CC cord, occipital pole, frontal lobe, temporal lobe, putamen,
CC amygdala, caudate nucleus, corpus callosum, hippocampus,
CC substantia nigra and thalamus. Weakly or not expressed in other
CC tissues.
CC -!- DOMAIN: Resistance to charybdotoxin (CTX) toxin is mediated by the
CC extracellular domain.
CC -!- PTM: Phosphorylated. Phosphorylation modulates its effect on
CC KCNMA1 activation kinetics.
CC -!- PTM: N-glycosylated. A highly glycosylated form is promoted by
CC KCNMA1. Glycosylation, which is not required for the interaction
CC with KCNMA1 and subcellular location, increases protection against
CC charybdotoxin.
CC -!- MISCELLANEOUS: Treatment with okadaic acid reduces its effect on
CC KCNMA1.
CC -!- SIMILARITY: Belongs to the KCNMB family.
CC --------------------------------------------------------------------------
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC --------------------------------------------------------------------------
DR EMBL; AF160967; AAF69805.1; -; mRNA. [EMBL / GenBank / DDBJ] [CoDingSequence]
DR EMBL; AF170917; AAF89699.1; -; mRNA. [EMBL / GenBank / DDBJ] [CoDingSequence]
DR EMBL; AF207992; AAF28333.1; -; mRNA. [EMBL / GenBank / DDBJ] [CoDingSequence]
DR EMBL; AF215891; AAF75596.1; -; mRNA. [EMBL / GenBank / DDBJ] [CoDingSequence]
DR EMBL; BC042446; AAH42446.2; -; mRNA. [EMBL / GenBank / DDBJ] [CoDingSequence]
DR EMBL; BC050621; AAH50621.2; -; mRNA. [EMBL / GenBank / DDBJ] [CoDingSequence]
DR Ensembl; ENSG00000135643; Homo_sapiens
DR HGNC; HGNC:6289; KCNMB4.
DR CleanEx; HGNC:6289; KCNMB4.
DR MIM; 605223; -. [NCBI / EBI]
DR GeneCards; KCNMB4.
DR GeneLynx; KCNMB4.
DR GenAtlas; KCNMB4.
DR SOURCE; KCNMB4.
DR GO; GO:0008076; C:voltage-gated potassium channel complex; IDA.
DR GO; GO:0015269; F:calcium-activated potassium channel activity; IDA.
DR GO; GO:0015459; F:potassium channel regulator activity; TAS.
DR GO; GO:0005515; F:protein binding; IDA.
DR GO; GO:0005513; P:calcium ion sensing; IDA.
DR GO; GO:0019228; P:generation of action potential; IDA.
DR GO; GO:0006813; P:potassium ion transport; IDA.
DR GO; GO:0001508; P:regulation of action potential; IDA.
DR GO; GO:0046928; P:regulation of neurotransmitter secretion; TAS.
DR GO; GO:0019229; P:regulation of vasoconstriction; TAS.
DR GO; GO:0007268; P:synaptic transmission; TAS.
DR InterPro; IPR003930; BK_channel_beta.
DR InterPro; Graphical view of domain structure.
DR PANTHER; PTHR10258; BK_channel_beta; 1.
DR Pfam; PF03185; CaKB; 1.
DR Pfam; Graphical view of domain structure.
DR CMR; Q86W47.
DR ProDom [Domain structure / List of seq. sharing at least 1 domain]
DR HOVERGEN [Family / Alignment / Tree]
DR BLOCKS; Q86W47.
DR ProtoNet; Q86W47.
DR ProtoMap; Q86W47.
DR PRESAGE; Q86W47.
DR DIP; Q86W47.
DR ModBase; Q86W47.
DR SWISS-2DPAGE; GET REGION ON 2D PAGE.
KW Glycoprotein; Ion transport; Ionic channel; Phosphorylation;
KW Polymorphism; Transmembrane; Transport.
FT TOPO_DOM 1 19 Cytoplasmic (Potential).
FT TRANSMEM 20 40 1 (Potential).
FT TOPO_DOM 41 167 Extracellular (Potential).
FT TRANSMEM 168 188 2 (Potential).
FT TOPO_DOM 189 210 Cytoplasmic (Potential).
FT CARBOHYD 53 53 N-linked (GlcNAc...).
FT CARBOHYD 90 90 N-linked (GlcNAc...).
FT VARIANT 199 199 V -> I.
FT /FTId=VAR_018178.
FT MUTAGEN 11 11 T->A: Suppresses the effect of okadaic
FT acid and increases activation time
FT constant; when associated with A-17 and
FT A-210.
FT MUTAGEN 11 11 T->D: Suppresses its effect on KCNMA1
FT channel activation and on deactivation
FT kinetics; when associated with E-17 and
FT E-210.
FT MUTAGEN 17 17 S->A: Suppresses the effect of okadaic
FT acid and increases activation time
FT constant; when associated with A-11 and
FT A-210.
FT MUTAGEN 17 17 S->E: Suppresses its effect on KCNMA1
FT channel activation and on deactivation
FT kinetics; when associated with D-11 and
FT E-210.
FT MUTAGEN 53 53 N->A: Loss of N-glycosylation and reduced
FT protection against charybdotoxin; when
FT associated with A-90.
FT MUTAGEN 90 90 N->A: Loss of N-glycosylation and reduced
FT pr$otection against charybdotoxin; when
FT associated with A-53.
FT MUTAGEN 210 210 S->A: Suppresses the effect of okadaic
FT acid and increases activation time
FT constant; when associated with A-11 and
FT A-17.
FT MUTAGEN 210 210 S->E: Suppresses its effect on KCNMA1
FT channel activation and on deactivation
FT kinetics; when associated with D-11 and
FT E-17.
SQ SEQUENCE 210 AA; 23949 MW; A59D56DD034F027A CRC64;
MAKLRVAYEY TEAEDKSIRL GLFLIISGVV SLFIFGFCWL SPALQDLQAT EANCTVLSVQ
QIGEVFECTF TCGADCRGTS QYPCVQVYVN NSESNSRALL HSDEHQLLTN PKCSYIPPCK
RENQKNLESV MNWQQYWKDE IGSQPFTCYF NQHQRPDDVL LHRTHDEIVL LHCFLWPLVT
FVVGVLIVVL TICAKSLAVK AEAMKKRKFS
//